NCT02376166View on ClinicalTrials.gov

Metformin for Rising PSA Remote Trial

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Metformin

850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade \> 1 toxicities)

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Matthew Galsky

OTHER

NCT02376166 - Metformin for Rising PSA Remote Trial | Biotech Hunter | Biotech Hunter